Current Report Filing (8-k)
May 06 2019 - 4:18PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of
report (Date of earliest event reported)
May 2, 2019
MEDITE CANCER DIAGNOSTICS,
INC.
(Exact
Name of Registrant as Specified in Charter)
Delaware
(State
or Other Jurisdiction of Incorporation)
|
333-143570
|
36-4296006
|
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
|
10524 Moss Park Rd., Ste. 204-357
|
|
|
Orlando,
FL
|
32832
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
(407)
996-9630
(Registrant’s
telephone number, including area code)
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General Instruction A.2.
below):
|
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
|
Item
5.02
|
Departure
of Directors or Principal Officers, Election of Directors,
Appointment of Principal Officers.
|
On May 2, 2019, the Board of Directors (the “Board”) of
MEDITE Cancer Diagnostics, Inc. (the “Company”)
accepted the resignation of its Chief Executive Officer, President
and Director, Elmar A. Dave, effective immediately.
|
Item
9.01
|
Financial
Statements and Exhibits
|
|
Exhibit
No.
|
|
Description
|
|
|
|
Resignation Letter
of Elmar A. Dave dated May 2, 2019
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
MEDITE
CANCER DIAGNOSTICS, INC.
|
|
|
|
|
|
|
|
|
|
Date:
May 6, 2019
|
By:
|
/s/ William Austin Lewis IV
|
|
|
|
William
Austin Lewis IV
|
|
|
|
Chairman
of the Board
|
|
2
|
Medite Cancer Diagnostics (CE) (USOTC:MDIT)
Historical Stock Chart
From Nov 2024 to Dec 2024
Medite Cancer Diagnostics (CE) (USOTC:MDIT)
Historical Stock Chart
From Dec 2023 to Dec 2024
